Loading...

UK Government And NHS Spending Will Unlock Enduring Opportunities

Published
17 Feb 25
Updated
05 Sep 25
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-28.4%
7D
1.8%

Author's Valuation

₹3.09k26.1% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on 05 Sep 25

With both the discount rate and future P/E for Mastek remaining essentially unchanged, the consensus analyst price target was maintained at ₹3093. What's in the News Upcoming board meeting to review June 2025 quarterly financial results and consider re-appointment of Suresh Vaswani as Independent Director for a second term.

Shared on 01 May 25

Fair value Increased 6.77%

Shared on 23 Apr 25

Fair value Decreased 11%

AnalystConsensusTarget has decreased revenue growth from 13.9% to 12.1%.

Shared on 17 Apr 25

Fair value Decreased 0.58%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 4.11%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 3.57%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Decreased 3.41%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Increased 3.33%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 13 Mar 25

Fair value Increased 7.73%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.